PERTH, Australia - Singapore-based S*BIO and U.S.-based Onyx Pharmaceuticals are expanding their development collaboration to include additional indications for S*BIO's novel JAK2 inhibitors, the companies announced May 4
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
